Theranexus
Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Manufacturing
Description
THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-01-20 18:00 |
THERANEXUS PUBLIE SON AGENDA FINANCIER 2020
|
French | 297.2 KB | ||
| 2020-01-20 18:00 |
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2020
|
English | 275.9 KB | ||
| 2020-01-15 18:00 |
THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING T…
|
English | 380.8 KB | ||
| 2020-01-15 18:00 |
THERANEXUS ANNONCE LES RÉSULTATS CLINIQUES DE SON ÉTUDE DE PHASE IB MONTRANT UN…
|
French | 392.2 KB | ||
| 2019-12-12 18:00 |
Theranexus et la fondation BBDF annoncent la conclusion d'un accord de licence …
|
French | 444.0 KB | ||
| 2019-12-12 18:00 |
Theranexus and Beyond Batten Disease Foundation (BBDF) announce the signing of …
|
English | 361.6 KB | ||
| 2019-10-15 18:00 |
THERANEXUS REPORTS CASH POSITION AS OF SEPTEMBER 30, 2019
|
English | 249.4 KB | ||
| 2019-10-15 18:00 |
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2019
|
French | 257.3 KB | ||
| 2019-09-26 18:00 |
THERANEXUS ANNOUNCES ITS FIRST HALF 2019 RESULTS
|
English | 401.9 KB | ||
| 2019-09-26 18:00 |
THERANEXUS ANNONCE SES RÉSULTATS DU PREMIER SEMESTRE 2019
|
French | 306.5 KB | ||
| 2019-09-24 18:30 |
A NEW MILESTONE REACHED FOR THERANEXUS: INCLUSION OF LAST PATIENT IN PHASE II T…
|
English | 286.8 KB | ||
| 2019-09-24 18:30 |
NOUVELLE ETAPE FRANCHIE POUR THERANEXUS : INCLUSION DU DERNIER PATIENT DANS L'E…
|
French | 296.7 KB | ||
| 2019-09-17 07:30 |
THERANEXUS ANNONCE L'INCLUSION DU DERNIER SUJET DANS SON ÉTUDE DE PHASE 1B POUR…
|
French | 288.8 KB | ||
| 2019-09-17 07:30 |
THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201
|
English | 398.9 KB | ||
| 2019-09-03 09:45 |
THERANEXUS ANNOUNCES THE PUBLICATION OF TWO SCIENTIFIC PAPERS AND A PRESENTATIO…
|
English | 395.5 KB |
Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Theranexus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Theranexus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
